AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16183735 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider attitudes
Number of subjects: 32
Study 12932604 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day for 8 weeks
Number of subjects: 33
Study 12932604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11383021 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam
Number of subjects: 49
Study 11383021 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin composite
Number of subjects: 49
Study 11383021 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Number of subjects: 49
Study 8667129 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronal scaling (CS)
Number of subjects: 82
Study 8667129 — intervention group
Group type: EXPERIMENTAL
Intervention: Root planing (RP)
Number of subjects: 82
Study 8667129 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Widman surgery (MW)
Number of subjects: 82
Study 8667129 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap with osseous surgery (FO)
Number of subjects: 82
Study 8667129 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive periodontal treatment (SPT)
Number of subjects: 82
Study 1297876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardil, 240‐360 mg/day
Number of subjects: 74
Study 1297876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordafen, 30‐60 mg/day
Number of subjects: 74
Study 30908408 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging weight loss intervention
Number of subjects: 188
Study 30908408 — intervention group
Group type: COMPARATOR
Intervention: Control group (website only)
Number of subjects: 188
Study 28039317 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon β‐1a (sc IFN β‐1a) three times weekly (tiw)
Number of subjects: 402
Study 28039317 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon β‐1a (sc IFN β‐1a) once weekly (qw)
Number of subjects: 402
Study 28039317 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (DT)
Number of subjects: 402
Study 28039317 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon β‐1a (sc IFN β‐1a) tiw
Number of subjects: 402
Study 28039317 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon β‐1a (sc IFN β‐1a) qw and tiw
Number of subjects: 402
Study 25559065 — intervention group
Group type: EXPERIMENTAL
Intervention: BCQB 180μg alone
Number of subjects: 33
Study 25559065 — intervention group
Group type: EXPERIMENTAL
Intervention: BCQB 180μg co-administered with paroxetine 20mg
Number of subjects: 33
Study 25559065 — intervention group
Group type: EXPERIMENTAL
Intervention: BCQB 180μg in Study B (Group A)
Number of subjects: 33
Study 25559065 — intervention group
Group type: COMPARATOR
Intervention: Roxithromycin 150mg in Study B (Group B)
Number of subjects: 33
Study 23817631 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological treatment with infliximab
Number of subjects: 204
Study 23817631 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment with sulfasalazine plus hydroxychloroquine
Number of subjects: 204
Study 21062337 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalloped implant group (20 patients)
Number of subjects: 40
Study 21062337 — intervention group
Group type: COMPARATOR
Intervention: Flat implant group (20 patients)
Number of subjects: 40
Study 21062337 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 19389107 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant ALA-PDT after CO(2) laser ablation (n=84)
Number of subjects: 175
Study 19389107 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant placebo-PDT after CO(2) laser ablation (n=91)
Number of subjects: 175
Study 18821458 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy for Depression in Drug Dependence (BTDD)
Number of subjects: 38
Study 18821458 — intervention group
Group type: COMPARATOR
Intervention: Structured relaxation intervention (REL)
Number of subjects: 38
Study 18821458 — intervention group
Group type: EXPERIMENTAL
Intervention: Both BTDD and REL
Number of subjects: 38
Study 16505753 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Sedation (PCS) with propofol (20-mg boluses)
Number of subjects: 72
Study 16505753 — intervention group
Group type: COMPARATOR
Intervention: Standard sedation (control group) with continuous infusion of propofol
Number of subjects: 72
Study 12443589 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound scan (invited group, n=33839)
Number of subjects: 67800
Study 12443589 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=33961, no screening)
Number of subjects: 67800
Study 12443589 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended screening (subgroup of invited group)
Number of subjects: 67800
Study 12443589 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective surgery for an aneurysm
Number of subjects: 67800
Study 12443589 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency surgery for an aneurysm
Number of subjects: 67800
Study 10611625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresenius AS104
Number of subjects: 20
Study 10611625 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenwal Amicus
Number of subjects: 20
Study 10611625 — intervention group
Group type: EXPERIMENTAL
Intervention: COBE Spectra Version 7 (Turbo)
Number of subjects: 20
Study 10611625 — intervention group
Group type: COMPARATOR
Intervention: COBE Spectra Version 5 (V5‐LRS)
Number of subjects: 20
Study 7494655 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose 50% (2 mL)
Number of subjects: 16
Study 7494655 — intervention group
Group type: COMPARATOR
Intervention: Placebo (distilled water, 2 mL)
Number of subjects: 16
Study 1702944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 60
Study 1702944 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline
Number of subjects: 60
Study 7049296 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive home visiting from community psychiatric nurses
Number of subjects: 71
Study 7049296 — intervention group
Group type: COMPARATOR
Intervention: Routine psychiatric out‐patient care
Number of subjects: 71
Study 7049296 — intervention group
Group type: EXPERIMENTAL
Intervention: Community psychiatric nursing
Number of subjects: 71
Study 31995035 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 96
Study 31995035 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96
Study 30447348 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution 10% for about 1 min
Number of subjects: 226
Study 30447348 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaginal cleansing)
Number of subjects: 226
Study 29058628 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (two sessions per week for one hour)
Number of subjects: 40
Study 29058628 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle change advice (control group)
Number of subjects: 40
Study 25520214 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose administration
Number of subjects: 32
Study 25520214 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 32
Study 24369366 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast ForWord® exercises in a game‐like format, 30 sessions
Number of subjects: 81
Study 24369366 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 81
Study 22314101 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng extract (9 capsules per day for 3 months)
Number of subjects: 100
Study 22314101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (9 capsules per day for 3 months)
Number of subjects: 100
Study 19413910 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking School Bus (WSB) program
Number of subjects: 653
Study 19413910 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 653
Study 17331082 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diet and exercise intervention
Number of subjects: 137
Study 17331082 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet alone
Number of subjects: 137
Study 17331082 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise alone
Number of subjects: 137
Study 17331082 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 137
Study 14698828 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (TCA) after dilatation and curettage
Number of subjects: 90
Study 14698828 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (TCA) after administration of danazol
Number of subjects: 90
Study 14698828 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid (TCA) after administration of goserelin acetate
Number of subjects: 90
Study 14698828 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 90
Study 14698828 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin group
Number of subjects: 90
Study 11556125 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated pellets containing 75 mg diclofenac sodium (A)
Number of subjects: 16
Study 11556125 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated tablet with 50 mg diclofenac sodium (B)
Number of subjects: 16
Study 11556125 — intervention group
Group type: COMPARATOR
Intervention: Capsule containing 140 mg diclofenac resinate (C)
Number of subjects: 16
Study 11556125 — intervention group
Group type: COMPARATOR
Intervention: Dispersible tablet containing 46.5 mg diclofenac acid (D)
Number of subjects: 16
Study 10021877 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenomegaly due to portal hypertension (17 patients)
Number of subjects: 24
Study 10021877 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenomegaly due to myeloproliferative disease (7 patients)
Number of subjects: 24
Study 10021877 — intervention group
Group type: COMPARATOR
Intervention: Control group (25 patients without splenomegaly)
Number of subjects: 24
Study 7798613 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde 1%
Number of subjects: 229
Study 7798613 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde 0.5%
Number of subjects: 229
Study 7798613 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde 0.1%
Number of subjects: 229
Study 7798613 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde 0.05%
Number of subjects: 229
Study 7798613 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde (0.5%, 0.1%, 0.05%)
Number of subjects: 229
Study 7798613 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinaldehyde
Number of subjects: 229
Study 3046408 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine
Number of subjects: 44
Study 3046408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 3046408 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 44
Study 27402729 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 0
Study 27402729 — intervention group
Group type: COMPARATOR
Intervention: Cognitive task
Number of subjects: 0
Study 27556896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal saline irrigations (NSI)
Number of subjects: 0
Study 27556896 — intervention group
Group type: COMPARATOR
Intervention: Non-irrigation
Number of subjects: 0
Study 25622123 — intervention group
Group type: EXPERIMENTAL
Intervention: 380 mg naltrexone injection + weekly psychotherapy for 4 weeks
Number of subjects: 22
Study 23514288 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E vaccine
Number of subjects: 447
Study 23514288 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine (control)
Number of subjects: 447
Study 20890238 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine (0.15%)
Number of subjects: 244
Study 20890238 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 244
Study 18353201 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence PF 10% (OPA)
Number of subjects: 50
Study 18353201 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 50
Study 17093898 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART (Highly Active Antiretroviral Therapy)
Number of subjects: 34
Study 12022462 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% AgNO3
Number of subjects: 0
Study 12022462 — intervention group
Group type: COMPARATOR
Intervention: Control (water soaking)
Number of subjects: 0
Study 10484048 — intervention group
Group type: EXPERIMENTAL
Intervention: D + T (Diet + Troglitazone)
Number of subjects: 0
Study 10484048 — intervention group
Group type: EXPERIMENTAL
Intervention: S + T (Sulfonylurea + Troglitazone)
Number of subjects: 0
Study 10484048 — intervention group
Group type: COMPARATOR
Intervention: Control group (only diet therapy)
Number of subjects: 0
Study 8564488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular mass heparin (LMMH) (70 anti‐Xa units/kg b.w.)
Number of subjects: 18
Study 8564488 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 18
Study 8564488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular mass heparin (LMMH)
Number of subjects: 18
Study 1769130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (2 mg/kg p.o.)
Number of subjects: 11
Study 1769130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7094779 — intervention group
Group type: EXPERIMENTAL
Intervention: Occult blood test in stool
Number of subjects: 48000
Study 7094779 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete colonic workup including colonoscopy
Number of subjects: 48000
Study 7094779 — intervention group
Group type: EXPERIMENTAL
Intervention: Air‐contrast barium‐enema examination
Number of subjects: 48000
Study 7094779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukes' A stage
Number of subjects: 48000
Study 7094779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukes' B stage
Number of subjects: 48000
Study 7094779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukes' C stage
Number of subjects: 48000
Study 7094779 — intervention group
Group type: EXPERIMENTAL
Intervention: Dukes' D stage
Number of subjects: 48000
Study 30323055 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cannabis (100 mg dose)
Number of subjects: 45
Study 30323055 — intervention group
Group type: COMPARATOR
Intervention: No cannabis
Number of subjects: 45
Study 26876657 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Case Management (ICM)
Number of subjects: 2148
Study 26876657 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 2148
Study 26876657 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 2148
Study 26876657 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (general)
Number of subjects: 2148
Study 25693050 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (SMS-based intervention)
Number of subjects: 366
Study 25693050 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (Control)
Number of subjects: 366
Study 23748474 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone (PB) 10 mg/kg/day on day 1 followed by 5 mg/kg/day on days 2-5
Number of subjects: 44
Study 23748474 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose (control)
Number of subjects: 44
Study 20946161 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (flexible-dose of 25, 50, or 100 mg)
Number of subjects: 176
Study 20946161 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 176
Study 18783652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral radiotracer administration (n=35)
Number of subjects: 80
Study 18783652 — intervention group
Group type: COMPARATOR
Intervention: Peritumoral radiotracer administration (n=45)
Number of subjects: 80
Study 18783652 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral radiotracer administration
Number of subjects: 80
Study 18783652 — intervention group
Group type: COMPARATOR
Intervention: Peritumoral radiotracer administration
Number of subjects: 80
Study 16815489 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 445
Study 12823113 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of asthma
Number of subjects: 15706
Study 12823113 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of allergic rhinitis
Number of subjects: 15706
Study 12823113 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of atopic eczema
Number of subjects: 15706
Study 12823113 — intervention group
Group type: EXPERIMENTAL
Intervention: Indices of diagnosis
Number of subjects: 15706
Study 12823113 — intervention group
Group type: EXPERIMENTAL
Intervention: Indices of severity
Number of subjects: 15706
Study 11120577 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2% ophthalmic solution
Number of subjects: 261
Study 11120577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 9372661 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-protective approach (LPA) with permissive hypercapnia (PHY), VT < 6 ml/kg, distending pressures above PEEP < 20 cm H2O, and PEEP 2 cm H2O above the lower inflection point on the static inspiratory P-V curve (P(FLEX))
Number of subjects: 48
Study 9372661 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation
Number of subjects: 48
Study 8092801 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone treatment
Number of subjects: 0
Study 8092801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3894871 — intervention group
Group type: COMPARATOR
Intervention: 50 g of glucose (G)
Number of subjects: 8
Study 3894871 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of fructose (F)
Number of subjects: 8
Study 3894871 — intervention group
Group type: COMPARATOR
Intervention: Sweet placebo (C)
Number of subjects: 8
Study 30365984 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoRings
Number of subjects: 927
Study 30365984 — intervention group
Group type: COMPARATOR
Intervention: standard
Number of subjects: 927
Study 28475473 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement (50,000 units, one every fortnight for 8 weeks)
Number of subjects: 89
Study 28475473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 26306589 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Magnesium to Creatinine ratio (Mg/Cr)
Number of subjects: 1403
Study 26306589 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Calcium to Creatinine ratio (Ca/Cr)
Number of subjects: 1403
Study 26306589 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Phosphorus to Creatinine ratio (P/Cr)
Number of subjects: 1403
Study 24767623 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraliminal training
Number of subjects: 56
Study 24767623 — intervention group
Group type: EXPERIMENTAL
Intervention: Masked training
Number of subjects: 56
Study 24767623 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 56
Study 22429479 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine administration
Number of subjects: 21
Study 20963997 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural drainage
Number of subjects: 50
Study 20963997 — intervention group
Group type: COMPARATOR
Intervention: Routine negative pressure drainage
Number of subjects: 50
Study 18080725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV)
Number of subjects: 40
Study 18080725 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation (VCV)
Number of subjects: 40
Study 16157604 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-in recruitment strategy
Number of subjects: 510
Study 16157604 — intervention group
Group type: COMPARATOR
Intervention: Opt-out recruitment strategy
Number of subjects: 510
Study 12841498 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium w (immuvac) as adjuvant therapy
Number of subjects: 0
Study 12841498 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy (cisplatin and etoposide) and radiotherapy (control group)
Number of subjects: 0
Study 10823753 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir
Number of subjects: 92
Study 10823753 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir
Number of subjects: 92
Study 10823753 — intervention group
Group type: COMPARATOR
Intervention: Control (no ganciclovir)
Number of subjects: 92
Study 8862741 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid and salt supplementation (0.1 g sodium chloride/kg body weight and 30 mL water/kg body weight) during hypokinesia
Number of subjects: 30
Study 8862741 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsupplemented hypokinetic subjects (2.7 km/d)
Number of subjects: 30
Study 8862741 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (14.0 km/d)
Number of subjects: 30
Study 1284155 — intervention group
Group type: EXPERIMENTAL
Intervention: Gallopamil (0.4 mg)
Number of subjects: 24
Study 1284155 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 24
Study 3890508 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin followed by oral warfarin
Number of subjects: 53
Study 3890508 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 53
Study 31393834 — intervention group
Group type: COMPARATOR
Intervention: s‐TDI measurements in SGA fetuses
Number of subjects: 120
Study 31393834 — intervention group
Group type: COMPARATOR
Intervention: s‐TDI measurements in LO-FGR fetuses
Number of subjects: 120
Study 31393834 — intervention group
Group type: COMPARATOR
Intervention: s‐TDI measurements in SGA and LO-FGR fetuses
Number of subjects: 120
Study 29155001 — intervention group
Group type: EXPERIMENTAL
Intervention: Left‐sided iliac crest bone graft (ICBG) harvesting
Number of subjects: 40
Study 29155001 — intervention group
Group type: EXPERIMENTAL
Intervention: Right‐sided iliac crest bone graft (ICBG) harvesting
Number of subjects: 40